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A B S T R A C T
There is an unmet need for new cardiovascular biomarkers. Despite this only few biomarkers for the
diagnosis or screening of cardiovascular diseases have been implemented in the clinic. Thousands of
proteins can be analysed in plasma by mass spectrometry-based proteomics technologies. Therefore, this
technology may therefore identify new biomarkers that previously have not been associated with
cardiovascular diseases. In this review, we summarize the key challenges and considerations, including
strategies, recent discoveries and clinical applications in cardiovascular proteomics that may lead to the
discovery of novel cardiovascular biomarkers.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cardiovascular disease (CVD) refers to any disease that affects
the cardiovascular system such as cardiac disease, vascular
diseases of the brain and kidney, and peripheral arterial disease.
The underlying pathology is often atherosclerosis, but may also
relate to other changes in the arterial systems (i.e. aneurysms,
increased stiffness) and different pathologies in the heart as well
(valvular alterations, cardiomyopathies etc.). CVD is the most
common cause of mortality in the western countries and the
prediction of cardiovascular events most often relies on the
monitoring of prevalent risk factors such as smoking habits,
diabetes, hyperlipidemia and hypertension [1]. Today, the corner-
stone diagnosis and monitoring of CVD among individuals are
clinical assessment of patients, imaging modalities together with
electrocardiography (EGG). Moreover, the prevention of CVD is
based on a strict management of the traditional risk factors of CVD;
smoking, diabetes, hyperlipidemia, and hypertension. Although
successful risk diminishing and effective treatment is available this
strategy is not viable for all CVD. For example, the majority of
individuals who actually develop manifest coronary heart disease
have rarely more than one of the conventional risk factors and thus* Corresponding author at: Department of Clinical Biochemistry and Pharmacol-
ogy, Centre for Clinical Proteomics, Odense University Hospital, Sdr. Boulevard 25,
DK-5000 Odense, Denmark. Tel.: +45 29647470.
E-mail address: hans.christian.beck@rsyd.dk (H.C. Beck).
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2212-9634/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article unfalls in to the low risk or intermediate risk group, which
complicates the risk stratiﬁcation before manifest disease occur
[2]. Therefore new proteomic biomarkers are needed to support
the information obtained from the conventional risk factors to
improve the stratiﬁcation of patients and to provide treatment at a
personalized level. The recent advances in method development,
bioinformatics and instrument speed, sensitivity, resolution and
dynamic range of mass spectrometers used in proteomics hold
the promise that the proteomics ﬁeld will be a signiﬁcant
contributor of plasma markers enabling the prediction of early
onset of CVD and treatment of the speciﬁc CVD at a personalized
level.
In present work we summarize the proteomics platforms
applied in cardiovascular plasma proteomics and also review the
recent achievement in plasma proteomics related to cardiovascular
diseases that may lead to new protein biomarkers with the
potential for developing into a future clinical protein test.
2. Biomarkers for cardiovascular disease
A biomarker may serve a variety of functions when used in a
clinical context. It has been deﬁned as a “characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to therapeutic intervention” [3] and serve various
functions corresponding to different stages in disease evolution.
Thus, biomarkers may be considered as indicators of disease trait
(risk factor or risk marker), disease state (preclinical of clinical), order the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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grouped into (1) risk stratiﬁcation biomarkers (identifying the
risk of developing a disease), (2) screening biomarkers (screening
for subclinical diseases), (3) diagnostic biomarkers (recognizing
overt disease), (4) staging biomarkers (categorizing disease
severity), or (5) prognostic biomarkers (predicting future disease
course, recurrence and therapy response) [3]. A biomarker for CVD
is not limited to a speciﬁc molecule (e.g. protein, RNA, or a
metabolite) measured in a biological sample such as body ﬂuids
(plasma, urine, cerebrospinal ﬂuids) or tissue, but may also be a
recording of physical parameters such as a person’s blood pressure,
electrocardiogram, echocardiogram or computerized tomography
(CT) scan.
Ideally, a biomarker for a CVD should enhance the ability of the
clinician to manage the patient in an optimal way. Although
proteomics technologies can identify and quantify thousands of
proteins and several studies have proposed a variety of protein
biomarkers for CVD only a limited number of plasma or serum
biomarkers have been implemented successfully into cardiology
practice – most of them being of diagnostic markers (Table 1).
These include, for example, the myocardium-speciﬁc structural
proteins troponin I and troponin T for the diagnosis of myocardial
injury [5] and B-type natriuretic peptide (BNP) that is a hormone
released from the ventricles during myocardial stress and used for
the diagnosis and management of acute congestive heart failure.
They form the cornerstone for the diagnosis of myocardial
infarction and myocardial stress. Moreover, it has been demon-
strated that – when measured with high sensitive assays – these
markers have the potential to be risk prediction markers. In fact,
several studies have demonstrated that within the reference level
there is a risk gradient corresponding to an increased risk of an
adverse cardiac event with increased troponin levels [6–8].
However, none of the routinely used protein biomarkers for
CVD have initially been found in proteomics discovery
experiments.
3. The plasma proteome – the never-ending challenge
Circulating blood is a convenient source for sampling and can be
collected without any interventional procedures. This is probably
the main reason that most proteomic biomarker discovery studiesTable 1
Commonly used diagnostic and prognostic plasma protein biomarkers for cardiovascul
Protein
biomarker
Origin Pathology 
Brian
natriuretic
peptide (BNP)
Secreted from membrane granules in
the cardiac ventricles – cardiac speciﬁc
Congestive heart failure, a
Troponin T
(TnT)
Cardiac-speciﬁc isoform, released upon
myocardial injury
AMI, myocardial injury 
Troponin I (TnI) Cardiac-speciﬁc isoform, released upon
myocardial injury
AMI, myocardial injury 
Creatinine
kinase/CK-
MB
Primarily released from the cardiac
muscle-not tissue speciﬁc
AMI, myocardial necrosis 
C-reactive
protein
Liver-produced non-speciﬁc acute-
phase reactant
Atheromatic plaque vulne
vasospasm, left ventricula
infarction.
Myoglobin Cardiac muscle – tissue unspeciﬁc Tissue necrosis, AMI, MI 
Apolipoprotein
(A)
Liver, intestine None 
Apolipoprotein
(a)
Liver, intestine None 
Apolipoprotein-
B100
Liver None have been done on circulating biomarkers and not on site-speciﬁc
blood samples. Although advantageous, this has also some
serious drawbacks; the discovered biomarkers – unless organ or
disease-speciﬁc like troponin T for myocardial damage – may
reﬂect the disease state of any organ in the body. Moreover, the
circulating biomarker will also suffer from a poor signal-to-noise
ratio. This may lead to poor predictive value and limited clinical use
of the identiﬁed biomarker. Signal-to-noise ratio can be increased
by sampling the blood distal to the diseased tissue, where the
biomarker concentration most probably will be highest [9]. This
strategy for blood sampling requires an interventional procedure
and will not be feasible in most plasma biomarker discovery
projects.
The most challenging feature of the plasma proteome with
respect to proteomics biomarker discovery, however, is the
presence of an exceptional wide concentration range of the
proteins comprising this proteome. Today, more than 10,000
proteins have been identiﬁed in human plasma (http://www.
plasmaproteomedatabase.org). The extreme concentration range
of proteins (12 orders of magnitude) ranging from >600 mM to the
low femtomolar level per litre of blood [10] and the set of
extremely high abundant proteins (such as serum albumin,
immunoglobulins and complement factors) that constitute more
than 99% of the total protein amount makes the plasma proteome
to the most heterogeneous and complex sub-proteome of the
human body [11,12]. As a consequence, discovering and validating
novel protein biomarkers for CVD such as atherosclerosis in plasma
is very challenging. This dramatically impacts the results that can
be obtained by proteomic discovery experiments on plasma
samples that should not be compared with the results from
proteomic discovery studies on tissue or cell models with the
respect to number of identiﬁed and quantiﬁed proteins. These facts
have driven the evolvement of several proteomic experimental
approaches that have been applied for the discovery of new plasma
biomarkers for CVD diseases. Many of these have applied highly
advanced analytical strategies to overcome the two major
obstacles in plasma discovery proteomics; the complexity of
plasma (number of proteins and the presence of many post-
translational modiﬁed proteins) and the extreme dynamic range of
plasma proteins conﬁning the number of identiﬁable and
quantiﬁable proteins. Another important issue is the number ofar diseases.
Use References
cute coronary syndrome Diagnostic,
prognostic
[61,62–64]
Diagnostic [65,66]
Diagnostic [65,66]
Diagnostic [67]
rability, coronary artery disease, coronary
r dysfunction, angina pectoris, myocardial
Screen for risk of
CVD
[68–70]
Diagnostic [71]
Prognostic,
screen for risk of
CVD
[72–74]
Prognostic,
screen for risk of
CVD
[72–74]
Prognostic,
screen for risk of
CVD
[75,76]
42 H.C. Beck et al. / Translational Proteomics 7 (2015) 40–48samples (individuals) to be included in a study and if data about
biological variation should be addressed already in the initial
discovery experiments. Most plasma proteome studies rely on
mixing of individual samples, i.e. typically pooling of samples from
healthy individuals and samples from diseased and comparing
proteins in the two pooled samples by proteomics in an unbiased
and quantitative manner. This approach does however not give
information on biological variations of the individual protein
concentrations. Since some highly relevant biomarkers display low
inter-individual variation and only small differences in average
values between cases and controls (for example albumin as a
marker for disease activity in many diseases) [13], and since many
proteins have extremely high inter-individual variation and may
display apparently large (but insigniﬁcant) fold changes between
different groups [14], both false positive and false negative results
occur in typical pooling experiments. It is therefore important to
take biological variation into account at a point in the biomarker
discovery pipeline, optimally as early as possible. Nevertheless,
only a minor part of studies rely on the quantitative proteomic
analysis of a number of individual samples (often a limited
number), which gives some insight into biological variation. In any
case, follow-up studies, where a number of potential candidates
are quantitated by immunoassay or multiplexed MRM, are needed
to ensure that selected candidate biomarker proteins can be
validated. Thus, with the present most used approach, which
include pooling of samples in the initial steps of the proteomic
discovery design, it is likely that many potentially clinical useful
biomarkers with relative small absolute differences betweenA B
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Fig. 1. Schematic representation of recent proteomic experimental stragroups are not considered due to false-negative neglections based
only on fold changes.
4. Important considerations for the experimental design of a
plasma proteome study
A plethora of pre-analytical variables inﬂuence the outcome of
the ﬁnal discovery analysis of a plasma sample, and the lack of
standardized procedures in all pre-analytical steps account for the
vast majority of errors during this process. Hence, for a successful
production of validated plasma biomarkers utmost attention
should be paid on the process of blood collection, the nature of
the sample container, lag-time prior to sample processing,
temperature (storage conditions and no. of freeze–thaw cycles),
and processing [15]. For example, the needs for pre-analytical
standardization was demonstrated by Marshall et al. [16] in a study
where MALDI-TOF was used for the analysis of blood samples from
patients with myocardial infarction. They found that the detected
changes in the protein proﬁles were caused by protease activities
rather than a result of the disease processes. It should also be noted
that the type of sample and sample processing may be quite
different in the different phases of biomarker development and
biomarker validation. For example, a typical plasma proteome
discovery project includes multiple sample processing steps such
as depletion, enrichment, chemical labelling, and pre-fractionation
prior to MS analysis (Fig. 1). By contrast, the sample processing in
the validation phase applying multiple reaction monitoring massC
case/control s
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tegies oriented to the identiﬁcation of plasma biomarker of CVD.
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processing step of the discovery phase: reduction and alkylation
followed by proteolytic cleavage [14].
Furthermore, features that are unique to cardiovascular
conditions will also inﬂuence the overall experimental setup for
a given study. A chronic condition that has evolved over decades
may often lead to an altered gene expression and therefore also a
change in the plasma protein levels of speciﬁc plasma proteins
produced by the liver or proteins related to the endothelial cells,
arterial smooth muscle cells or the extracellular matrix of the
arterial matrix. For example, atherosclerosis evolves over decade
with an equivalent slow change in the composition of the arterial
protein matrix and plasma protein composition. Here, the timing
of sampling is less important. By contrast, in acute cardiac
conditions or when acute insults induce rapid post-translational
modiﬁcations (PTM) of pre-existing proteins, the promptness of
the plasma proteome modulation should be taken into account and
the timing for collecting becomes more critical. Ideally, blood
samples should be collected before under and after the onset of the
disease allowing each subject to serve as its own control. For
example, in a study aiming the identiﬁcation of early biomarkers of
cardiac injury blood samples were collected directly from the
hearts of patients undergoing a planned myocardial infarction for
treatment of hypertrophic cardiomyopathy hearts, before, during
and after a controlled myocardial injury [17]. This design secured
the enrichment for candidate protein biomarkers of myocardial
infarction and concomitant proteomic analysis revealed more than
100 novel candidates for this disease by a label-free, relative
quantiﬁcation approach. A targeted proteomic approach based on
accurate inclusion mass screening actually qualiﬁed a fraction of
these candidates in peripheral plasma. A veriﬁcation study of
peripheral plasma from controls and patients with planned
myocardial infarction or spontaneous myocardial infarction by
MRM or immunoassays suggested a speciﬁcity of the analysed
markers towards myocardial infarction. Another important cause
of variation to be considered in proteomic plasma biomarker
discovery is the biological variation (between subject variation) for
a speciﬁc plasma protein within the individuals (case and control
group) of the study on top of the experimental variation of the
proteomic platform applied in the study. In ideal cases both
the baseline variation over time within individual and also the
variation between multiple individuals for each of the analysed
plasma proteins are determined. Practically, this is a rare case in
plasma proteome discovery studies as these most often are
performed on pooled samples (pool of samples from healthy
individuals’ vs. group of diseased). Pools are then analysed with
technical replicates or a rather low number of individual samples
(healthy and diseased analysed individually). Candidate biomark-
ers are given by a pre-deﬁned ratio (most often a factor of 1.5–2)
relative to the pooled sample from healthy individuals or by
statistical evaluation of relative peptide ratios [18]. This approach
results in the identiﬁcation of several biomarker candidates in
typical discovery experiments. There is a risk, however, that the
selected biomarker candidates will turn out to be not statistical
signiﬁcant due to the high inter-individual variation in protein
abundance among the samples analysed or that the sample pooling
will push individual proteins below the detection limit of the
applied technology [19]. Moreover, it is also possible that this
approach will exclude further investigations of candidates, which
may be important since many relevant biochemical changes in
plasma components does not necessarily show high fold change
differences between healthy and disease. In cell models or tissue
samples a typical proteomic experiment often quantiﬁes
>2000 proteins. Of them many hundreds meet the pre-deﬁned
criteria for a potential biomarker candidate that should be
considered for further evaluation using targeted quantitativeapproached such as MRM or immuno-chemical methods (ELISA) in
a rather large patient cohort as a ﬁrst step of validation. This
strategy is in many cases not viable due to very high cost and
enormous workload required for validating this number of
candidate with the current standard methods (MRM and/or ELISA).
Therefore, the list with candidates is reduced by means of
bioinformatics analysis to identify likely disease-relevant candi-
dates, by selecting on the basis of an intellectual assessment by the
researcher, or simply just by selecting the most regulated ones.
Each of the three mentioned approaches will result in an erroneous
exclusion of “real” disease-relevant candidate markers thus
leading to the selection of a relative high number of “false
positive” candidates for further validation. This is mainly because
the selection biased due to “expected” ﬁndings or the fact that the
regulation of disease-relevant protein markers not necessarily
correlate with pathological impact. Therefore it may be advanta-
geous that the proteomic discovery experimental setup is based on
samples from individuals instead of pooling samples. The major
advantages of this approach is a signiﬁcant reduction in “false
positive” candidates as the biomarker candidate is selected on the
basis of statistical signiﬁcance that also take technical and inter
individual variation into account. This can in principle be done by
both label-free methods and labelling-based methods. Label-free
methods include spectral methods (counting the number of
peptide assigned to a protein in an MS/MS experiment) or area
under curve (AUC)/signal intensity measurements based on
precursor ion spectra [20,21] whereas common labelling methods
include dimethyl labelling [22] and isobaric tags for relative and
absolute quantitation (iTRAQ, TMT) [23,24].
A viable and affordable experimental labelling approach is to
apply an amine reactive mass tag-based strategy that in addition
to, samples from individuals (healthy and diseased) included in the
study also includes an internal standard (a laboratory control
sample, e.g. a pool of all samples to be analysed in the study or a
pool of the healthy or diseased individual of the study). Currently,
this chemistry allows the assessment up to eight (iTRAQ 8-plex
reagent [25]) or ten individuals (10-plex TMT reagent [26]) in a
single experiment thereby reducing the number of samples to be
analysed dramatically. For example, Yin et al. [27] in their search
for new-onset plasma biomarkers for atherosclerosis used this
approach in an 8-plex iTRAQ experimental setup where plasma
samples from 136 case–control pairs were randomly tagged by six
of the eight iTRAQ channels throughout all iTRAQ mixes (46 in
total) to eliminate age, gender, and examination bias while
ensuring that case-control pairs were assayed in the same iTRAQ
mix to maximize the precision of pair-wise comparisons (Fig. 1B).
The remaining two channels producing the m/z 113 and m/z
117 reporter ions were assigned to the reference samples (pools of
case and control samples). This experimental design allowed the
researcher to select candidate biomarkers for further validation on
the basis of statistical analysis; paired t-test to compare means
between cases and controls, and conditional logistic regression
models.
5. Reducing complexity and protein dynamic range in plasma is
essential in proteomics
Reducing sample complexity is crucial to achieve sufﬁcient
analytical depth of the plasma proteome. It has been estimated
that blood contains maybe more than 1,000,000 proteins when
taking the number of variants due to proteolytic processing, PTM,
splice variants, and SNIPS (single-nucleotide polymorphism) in
account [28]. On top of that, many biological interesting proteins
relevant to CVD are present at very low levels (nanomolar range).
For example, the cardiac markers troponin I and troponin T are
found in the low nanomolar range and the tumour necrosis factor
44 H.C. Beck et al. / Translational Proteomics 7 (2015) 40–48in the femtomolar range in pathological states and even lower
when measured in healthy states. Despite the tremendous
developments in the MS technology in this century the sample
complexity of the plasma proteome still exceeds the capability of
the MS instruments for several technical reasons. First, as the
number of peptides that elute from the chromatographic column
into the MS instrument in a given time increases with sample
complexity a higher proportion of the peptides will remain un-
sequenced by the MS instrument. Secondly, the huge dynamic
range of the plasma proteome (1012) far exceeds the dynamic
range of any MS instrument which at best is around four to ﬁve
orders of magnitude [29]. Consequently, on top of the instrumental
limitations such as dynamic range and speed of the MS instru-
ments different approaches to reduce sample dynamic range and
sample complexity and have evolved during time; depletion of
high abundant proteins using chemical or immune chemical
methods and/or chromatographic pre-fractionation of the sample.
Depletion of high-abundant plasma proteins is most often based
on immune depletion methods that are essentially based on multi-
afﬁnity removal systems (MARS) that target up to top 20 proteins
and in the plasma sample or even serial immune depletion by
MARS depletion followed by “SuperMix” depletion where the
second depletion step targets “ﬂow through” proteins from the
ﬁrst depletion step (Fig. 1B) [30]. The use of depletion systems
cause loss of approximately 99% of the sample and enables – when
combined with multidimensional separations approaches such as
strong cation exchange chromatography (SCX) or hydrophilic
interaction chromatography (HILIC) with nano-LC–MS/MS analysis
– the identiﬁcation of more than 1000 unique proteins [31]. Loss of
sample (plasma proteins) rarely causes experimental problems as
plasma on average has a protein concentration of approximately
70 mg per mL and the available amount of plasma available in
clinical settings is often several millilitres. Even in cases where
only very limited amount of plasma is available (mouse experi-
ments, plasma from new born, etc.), e.g. 10 mL plasma samples will
leave one with approximately 35 mg protein per individual for a
proteomic experiment which is sufﬁcient for a multidimensional
fractionation proteomic experiment – for example, a typical
ﬁrst dimension fractionation employing HILIC has a capacity of
30–40 mg providing 15–20 2 mg fractions that subsequently are
analysed by nano-LC–MS/MS analysis resulting in the quantiﬁca-
tion of at least 400–500 unique proteins (2 high conﬁdent peptides
per protein) in iTRAQ experiments (unpublished results, our
laboratory [14]). By contrast, when applying similar multidimen-
sional approached to tissue or cells as many as 6000–7000 conﬁ-
dently identiﬁed proteins are obtained (unpublished results, our
laboratory).
Another promising technology for the proteomic detection of
medium- and low-abundant proteins in plasma include the
combinatorial peptide ligand library (CPLL) approach [32]. This
technology uses a stoichiometric peptide library (say millions of
peptides) immobilized on a solid support (chromatographic beads)
that – in theory – binds all proteins in a proteome with similar
afﬁnity resulting in an enrichment of very dilute protein species
whereas sites (peptides) with afﬁnity for high abundant protein
species rapidly saturates resulting in a dilution of the high
abundant proteins. This enrichment approach was for example
used to detect circulating protein biomarkers for carotid athero-
sclerosis in coronary patients [33], and to search for plasma
biomarkers for aortic stenosis [34].
Other depletion approaches have been reported such as
dithiotrethiol precipitation of serum albumin [35], enrichment
of low molecular weight serum proteins by acetonitrile precipita-
tion [36], afﬁnity enrichment of speciﬁc plasma proteins by
chemical proteomics [37], and more recently, hydrogel particle
trapping of high-abundant plasma proteins [38]. Althoughpromising, none of these approaches have proven their robustness
and reproducibility in a clinical setting. A well-recognized concern
when using any protein depletion technology is the unintended
removal of low abundant proteins that speciﬁcally or nonspeciﬁ-
cally bind to the proteins targeted for depletion. Several studies
demonstrate that such losses occur when using immune-depletion
columns but at the same time also showed that such losses are
merely neglectable [39,40]. The reproducibility and robustness and
applicability in an automatic setup using LC or FPLC equipment
suggest the commercially available depletion columns to be the
technology of choice in a clinical biomarker discovery and
validation setup.
The protein dynamic range of plasma can be reduced by
multidimensional fractionation prior to the proteomic experiment.
The recent development in proteomic technologies and methods
for sample preparation and enrichment techniques mostly rely on
multidimensional liquid chromatography electrospray tandem
mass spectrometry (2DLC–ESI–MS/MS). In most cases the peptide
sample is off-line fractioned using separation methods that are
orthogonal to the ﬁnal reversed phase nano-LC–MS/MS analysis. At
the peptide level, SCX [41], HILIC [42], high pH reversed phase
chromatography [43] are the methods of choice, whereas and off-
gel electrophoresis [44] and SDS–PAGE gel slides and liquid-phase
IEF are the most commonly methods used at the protein level.
Actually, most proteomic studies in plasma rely on a combination
of sample depletion followed by pre-fractionation in order to gain
sufﬁcient analytical “depth” and to reduce sample complexity.
6. Recent discovery studies in cardiovascular plasma
proteomics
The establishment of viable proteomics platforms evolved
during the past decade – effective depletion and enrichment
methods combined with pre-fraction methods and the evolvement
from capillary LC systems with split-ﬂow to highly robust direct
nano-LC systems and the tremendous development of fast
scanning, high resolution and high sensitive mass spectrometers
– have severely outdated earlier plasma proteome studies in terms
of speed, number of biomarker candidates identiﬁed in each
discovery experiment. This clearly illustrated the fact that a total of
only 289 proteins were identiﬁed in plasma in 2002 [11] to a
number that exceeds 10,000. In other words, less much effort is
required today to similar results as at the onset of this century as
demonstrated by some recent proteomics discovery studies.
For example, a recent study by Yin et al. [27] searched for novel
plasma protein biomarkers of new-onset atheroschlerotic CVD
using a discovery mass spectrometry-based proteomic approach
based on a dual-stage protein depletion strategy followed by
8-plex iTRAQ labelling of tryptic peptides and SCX fractionation
into 9 fractions (Fig. 1B). Each of these fractions were then further
fractioned into 304 fractions by reversed-phase HPLC and directly
spotted onto a MALDI plate for MS/MS analysis by MALDI-TOF/TOF
analysis. By using this approach 831 proteins in 135 myocardial
infarction cases and 135 matched controls were quantiﬁed. Of
them were 587 present in >40 case-control pairs. Single marker
and multiple marker analysis adjusted for established clinical risk
factors demonstrated that seven proteins in aggregate (cyclophilin
A, CD5, MUC18, collagen-a1, [XVIII] chain, salivary a-amylase 1,
C-reactive protein, and multimerin-2) were highly associated with
myocardial infarct and signiﬁcantly improved its prediction as
compared with a statistical model with risk factors alone. Multiple
marker analysis of data from targeted analyses of 59 proteins by
MRM in 336 case-control pairs of atherosclerotic CVD revealed a
combination of four proteins (a-1-acid glycoprotein, paraoxonase
1, tetranectin, and CD5 antigen-like protein) that predicted
incident atherosclerotic CVD and also improved its prediction as
H.C. Beck et al. / Translational Proteomics 7 (2015) 40–48 45compared to a statistical model with risk factors alone. It is
noteworthy that, despite the great efforts that have been made to
reduce the dynamic range of the sample and reduce sample
complexity by the application of dual-stage immune-depletion
and peptide fractionation prior to MALDI-TOF/TOF analysis, only
587 proteins were quantiﬁed. Despite this approximately 10%
of them (59 proteins) qualiﬁed for further testing by MRM in
336 case–control pairs whereof seven proteins in aggregation
demonstrated a signiﬁcant association with myocardial infarct
(P < 0.0001). This study clearly demonstrates that it is possible to
develop plasma protein biomarkers from a fairly low number of
proteins quantiﬁed in the discovery study if only the number of
individuals in the study is large enough.
In another study, Kristensen et al. [14] searched for early onset
biomarker for atherosclerosis and used a quantitative proteomic
approach based on immuno-depletion of the most abundant
plasma proteins from pools of samples from individuals without
any cardiovascular symptoms and no sign of coronary calciﬁcation,
individuals with a high coronary calcium score, individuals that
had surgery because of an atherosclerotic diseases, and individuals
suffering from acute coronary syndrome (n = 30 in all four groups)
and four-plex iTRAQ labelling followed by HILIC and titanium
dioxide pre-fractionation, and nano-LC–MS/MS analysis. This
experiment allowed the simultaneous investigation of proteomic
changes occurring along with three manifestations of atheroscle-
rosis. This experimental approach quantiﬁed 731 unique plasma
proteins whereof 319 were only identiﬁed in the eluate from the
titanium dioxide fractionation step. This demonstrates the power
of adding an extra fractionation step that is selective towards a
speciﬁc chemical structure present on a subgroup of peptides – in
present case a phosphorylation. Using this approach 25 proteins
demonstrated a signiﬁcant altered expression as compared to the
control group in at least the group with individuals diagnosed with
acute coronary syndrome, several among them well-known
markers for CVD including apolipoprotein (a) (Apa(a)), C-reactive
protein (CRP), serum amyloid protein A (SAA), that previously has
been associated with CVD such as coronary heart disease,
myocardial infarction and stroke [45–48]. On top of the
identiﬁcation of well-described markers for CVD this study also
identiﬁed one novel marker, vinculin – a multi-linker protein
that acts as connector for cell–matrix adhesions and cell–cell-
adhesions to the actin-based cytoskeleton. This protein was the
top-most elevated protein identiﬁed in the study and its
expression was validated at single patient level means of MRM
whereas the known markers for CVD were validated using
immunoassays. Apo (a), CRP, and SAA were validated by both
immunoassays and MRM and this validation demonstrated a high
agreement between the two methods applied for validation. Major
drawback of this study is, however, that the discovery phase is
performed on pooled sample of a relative low number individuals
included in the study. Moreover, the validation of the top-most
regulated biomarker candidates by MRM analysis performed on
individual samples was performed on the same sample group as
the discovery phase.
A third recent proteomic study aimed for the discovery of novel
diagnostic biomarkers for acute decompensated heart failure
(ADHF) driven by the lack for suitable marker that could
discriminate ADHF patients with or without a history of chronic
heart failure (CHF) with sufﬁcient speciﬁcity and selectivity (the
former represent up to 80% of ADHF patients) [49]. Cardiac courses
of ADHF are diverse and include left ventricular diastolic and/or
systolic dysfunction, right ventricular dysfunction and/or acute
ischaemia [50] and the existing markers for ADHF, B-type
natriuretic peptides (BNP) released from stressed cardiomyocytes,
can diagnose ADHF with high sensitivity but cannot discriminate
between patients that have ADHF or patients with CHF but notADHF. Here, the COFRADIC (combined fractional diagonal chro-
matography) technology was used to compare plasma samples of
10 ADHF patients with 10 controls in order to identify novel protein
biomarkers for ADHF (Fig. 1C). With COFRADIC, the large dynamic
range of plasma proteins is circumvented by an N-terminal
enrichment strategy. This strategy included a two-step depletion
approach based on immune depletion of the top-14 proteins
followed by reduction and alkylation of free cysteine residues and
acetylation of free amines (a- and e-amines). The following trypsin
digestion produces two types of peptides: internal peptides with a
free a-amino group and acetyl-blocked N-terminal peptides. The
free N-terminal peptides are then blocked with 2,4,6-dinitroben-
zenesulfonic acid (TNB) to form highly hydrophobic peptides that
enables the isolation of the acetyl-blocked N-terminal peptide
fraction by reversed-phase HPLC. This fraction, that in principle
contain only N-terminal peptides, is separated by nano-LC and
directly spotted onto MALDI targets. A relative quantiﬁcation of
samples from ADHF patients with controls was done by means of
O16/O18-labelling following the trypsin digestion step. Statistical
analysis of microarray (SAM) of the proteomic data revealed
103 signiﬁcantly differentially regulated proteins whereof 49 pro-
teins were retained as potential candidates for further evaluation
in a larger patient cohort. A proof-of-concept of the discovery
platform was achieved by the detection of the “gold standard
marker” of HF; the natriuretic peptide pro-BNP and other
established markers such as C-reactive protein and cystatin-C.
MRM-based quantitative assays were developed for 27 of the
49 selected candidates. The clinical performance of the 27 chosen
candidates was tested in 267 prospectively collected individuals
(76 patients with acute HF, 71 patients with non-cardiac dyspnoea,
80 stable CHF patients, and 40 healthy controls). Downstream
analysis of the 27 marker candidates identiﬁed sulfhydryl oxidase 1
(QSOX1) to be highly sensitive and speciﬁc for ADHF diagnosis in
patients with acute dyspnoea and also signiﬁcantly reduced false
positives and demonstrated the highest speciﬁcity for ADHF
diagnosis in patients with dyspnoea. A major weakness of this
study is, however, that the discovery part of the work only include
10 healthy individuals that is compared with 10 diseased
individuals which is a rather low number of individuals to be
included for a discovery study. It is also not clear how many
proteins that a rather low number of individuals to be included for
a discovery study. It is also not clear how many proteins that were
quantiﬁed across all individuals. Furthermore, the protein identi-
ﬁcation and protein quantiﬁcation is likely to be based on single
peptide as – in theory – only the N-terminal tryptic peptide of each
protein is present after sample preparation. On top of that, several
steps in the sample preparation procedure include chemistries that
may affect the accuracy of this method.
7. From discovery to clinical value: status and perspectives
Once a biomarker candidate has been discovered it should be
conﬁrmed and validated in hundreds to thousands of specimens
before it can be brought into clinical (use) trials. Moreover, it
should be speciﬁc, sensitive and reproducible. The improved
robustness of proteomic discovery technologies has primed an
enormous number of discovery projects, but disappointing few
clinical useful biomarkers have been successfully validated for use
in clinical routine or research practice [51]. In fact, despite a nearly
exponential growth in the number of biomarker publications
during the past 10–15 years, the rate of the introduction of new
protein biomarker has remained surprisingly constant around
1–2 per year [52,53], and even more concerning, none of these
have been discovered by proteomics technologies [53,54]. These
facts strongly indicate serious deﬁciencies in the proteomic
biomarker discovery process that were addressed to be due lack
46 H.C. Beck et al. / Translational Proteomics 7 (2015) 40–48of suitable analytical platforms to verify candidate protein
biomarkers in large cohorts/sample sets [55], limited access to
clinical samples that are well-matched according to factors such as
CVD risk factors, medication, gender and age [56], the absence of a
proper organized biomarker development pipeline [57,58], and a
too empirical attitude to biomarker research [59].
The biggest reason, however, for the proteomic technology over
the past decades have not developed new CVD biomarkers and
biomarkers in other ﬁelds as well, is most probably due to
technological limitations. Despite the great excitement of the
technological development of the 2D PAGE technology up through
the 1980s and 1990s until 2002 the total number of proteins that
were identiﬁed in human plasma was 289 [11]. In retrospect – with
today’s knowledge that the human plasma proteome comprises
more than 10,000 proteins – the likelihood to discover novel
plasma protein biomarkers for CVD was very low. At that time the
technology shifted from being 2D gel-based to platforms consist-
ing of multidimensional chromatographic separations of crude
peptide mixtures combined with mass spectrometric analysis.
With this shift in technology, a variety of new sample preparation
methods, such as afﬁnity puriﬁcation of speciﬁc proteins or
removing high abundant proteins by immune chemical methods,
aiming the detection of low abundant proteins in human plasma
samples, have evolved. This, in combination with the recent
tremendous development in speed and sensitivity of mass
spectrometers and development of robust direct nano-ﬂow LC
systems enabled the development of robust proteomic workﬂows
and experimental designs (see, e.g. Fig. 1) that enabled the
in-depth proteomic analysis of plasma.
Another reason for the lack of discovery of clinically useful
protein biomarker by proteomics technologies may relate to the
fact that plasma from cases and controls are often not sampled in
the optimal situation, when considered from a clinical perspective.
There is no doubt that factors like fasting, time of day, timepoint in
the disease progression, comorbidities, and many others inﬂuence
protein concentrations. It is therefore essential that samples for
discovery studies, focused on ﬁnding clinical useful markers, are
sampled in thoughtful way. Optimally, sampling for studies that
aims at ﬁnding clinical relevant markers should therefore use
samples taken in the exact population where the clinical question
is relevant and at exactly the timepoint where the clinical question
is relevant. For example, if the idea is to develop a marker that may
help the clinician to discriminate between intracranial haemor-
rhage vs. arterial occlusion in patients with symptoms of stroke, it
is important to search for biomarkers in samples taken at exactly
the timepoint when this clinical question is relevant, for example
in a population with relevant neurological symptoms at arrival at
the hospital, not taken hours or days later. One challenge is that
these optimal plasma samples are seldom available. Moreover, in
such studies it is important to have good information concerning
the current gold standard for the clinical situation for which a
novel biomarker is intended.
Not every barrier to the discovery of new protein markers are,
however, related to the technology and challenges in the
proteomic analysis, it should also be mentioned that it is very
important for the clinical community to deﬁne which markers
could be of actual use either in research studies or in clinical
situations. For example, it is important to realize that it is not
necessarily important to search for and ﬁnd better estimates for
risk in a certain situation, if it does not help the clinician to
suggest a better management of the patient. Aspects in relation to
this issue should probably be part of the design of discovery
studies, i.e. the samples that are used for the search should reﬂect
the situation in which markers should be used. This is relevant for
all kind of markers, i.e. screening, diagnosis, prognosis, prediction
and also companion diagnostics. Another important barrier to thedevelopment of new CVD biomarkers could be that researchers
historically were looking for the “one and only” biomarker and
have not considered the potential of using combinatorial panels
of markers until recent years where proteomics technology has
enabled the quantiﬁcation of 1000s of plasma proteins instead of
a handful only one decade ago.
In fact, combining known biomarkers in a multiple biomarker
approach might in fact improve the prediction of the risk of
cardiovascular event. This was demonstrated by Wang et al. [60]
who measured the levels of 10 biomarkers and found that levels of
CRP, the urinary albumin-to-creatinine ratio, B-type natriuretic
peptide, homocysteine, and renin strongly predicted risk of death
whereas levels of B-type natriuretic peptide and the urinary
albumin-to-creatinine ration. When these biomarkers were
combined in multi-marker score, individuals with higher multi-
marker scores had a signiﬁcant increased risk of death and major
cardiovascular events than individuals with low multi-marker
scores. The impact of adding the multi-marker scores to the
standard risk factors did only result in a slight increase in the
ability to classify risk. This result was, however, somewhat
predictable as the measured biomarkers in this study and the
risk factors were beforehand correlated – thus interrogating
similar pathways and thereby acts as a proof-of-principle
experiment for the multi-marker approach and excellently
demonstrates the potential of applying novel biomarkers in a
multi-marker approach to improve the prediction of risk of
cardiovascular events.
In conclusion, the recent developments in the proteomic
discovery platforms allowing the detection of even the less
abundant plasma proteins, the establishment of an increasing
number of bio banks and collection of plasma samples, and the
development of even more endowed experimental designs will
undoubtedly lead to the discovery of CVD plasma biomarker
candidates that – alone or when used in combination – have a
larger potential to pass the validation phase and become the next
generation biomarker for CVD in the clinic.
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